Author Archive for: TG

Denmark-based Lundbeck has reported positive top-line results from the intravenous arm of its phase IIb PROCEED trial of bocunebart (Lu AG09222) in migraine prevention, putting the neuroscience specialist on course for phase III discussions with regulators. The milestone comes after the company was forced to abandon the drug’s subcutaneous formulation last year — a setback that had cast a shadow over the entire PACAP-targeting approach.

The European Commission has approved Amgen’s Uplizna in generalized myasthenia gravis, moving the big biotech into a market served by argenx, Johnson & Johnson and UCB.

Europe produces world-class life sciences research, yet still struggles to finance and scale it. Venture capital in European biotech accounts for just 7 per cent of global funding, while 66 of the 67 EU biotech companies that went public over the past six years chose to list outside Europe. Capital is available globally; Europe is struggling to capture it.

A surprise move from Darmstadt to Paris: outgoing Merck CEO Belén Garijo is set to take the helm at French pharmaceutical group Sanofi after Paul Hudson unexpectedly failed to secure a contract extension from the board.

Cambridge-based Microbiotica’s ulcerative colitis (UC) candidate met its primary and secondary phase 1b study objectives on safety, efficacy signals and bacterial engraftment. The company has reported positive results from a small, placebo-controlled study of its oral precision microbiome therapy MB310 in patients with mild-to-moderate ulcerative colitis, adding a rare positive clinical signal in a disease area where microbiome approaches have so far struggled to gain traction.